Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy ...

Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's ...

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...

Reports Q3 revenue $401.6M, consensus $382.2M. “Improving momentum in both the Hims and Hers brands delivered another strong quarter of ...

Says trajectory in 2024 “nothing short of phenomenal.” Says business trajectory setting “robust foundation” for 2025.

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.

Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the report.

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $20.36 which represents a slight increase of $1.53 or 8.13% from the prior close of $18.83. The stock opened at ...

Hims stock jumped late Monday after the online pharmacy beat expectations, helped by Hims & Hers' weight-loss drug.